by Daniel Gray | Sep 30, 2014 | Press Release
New York, NY – September 30, 2014 – CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class microglial modulator, as a potential treatment for Alzheimer’s disease (AD), announced today it has appointed former pharmaceutical senior executive Adrian...
by Daniel Gray | Feb 21, 2014 | Press Release
The Advisory Board includes internationally recognized clinicians and researchers in Alzheimer’s disease. February 21, 2014 – New York, NY– CereSpir™ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for...
by Daniel Gray | Jan 10, 2014 | Press Release
January 9, 2014 – New York, NY– CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator as a potential treatment for Alzheimer’s disease, today announced Chris Griffett, BSc (Hons), C.Biol., FTOPRA, will serve as the Company’s Vice...
by Daniel Gray | Nov 26, 2013 | Press Release
New York, NY – November 26, 2013 – CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer’s disease, announced today Richard Margolin, MD, has joined the Company as Vice President, Clinical...
by Daniel Gray | Nov 8, 2013 | Press Release
November 8, 2013 – New York, NY, and Parma, Italy – CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir has acquired the worldwide development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia...
by Daniel Gray | Jul 26, 2013 | Press Release
Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive function CHF 5074 is a first-in-class small molecule microglia modulator, the only compound of...
